The Application segment of the Tongxuan Lifei Pills market is divided into four primary therapeutic areas: cardiovascular, respiratory, digestive, and other indications. Cardiovascular usage accounts for the largest share, driven by the pill’s vasodilatory and anti‑platelet properties, which address hypertension and peripheral artery disease; it contributes roughly 45 % of total sales volume. Respiratory applications, encompassing asthma and chronic bronchitis management, represent about 30 % of the market, reflecting growing prevalence of airway disorders in the aging population. Digestive uses, such as treatment of gastritis and functional dyspepsia, generate 15 % of revenue, supported by the formulation’s anti‑inflammatory effect on the gastrointestinal mucosa. The residual 10 % falls under Other categories, including dermatological and metabolic conditions, where off‑label prescribing is limited but measurable. This application‑based taxonomy clarifies how each therapeutic niche underpins the overall Tongxuan Lifei Pills market size and informs resource allocation for R&D and marketing. Moreover, regulatory approvals and insurance reimbursement policies have reinforced the dominance of cardiovascular and respiratory sub‑segments, further skewing the revenue distribution toward these areas.
